The Covid-19 pandemic is a watershed event that made us all rethink and reimagine personal hygiene. We have learned the dangers of letting harmful pathogens move freely within our populations. In our new reality, it is imperative that we adopt new behaviours which could prevent widespread illness and promote more robust personal health at the individual level. In addition to masking up and washing our hands, there is definitely room for innovations which allow us to move through life with more confidence and reassurance. In the darkest of times there are always lessons on offer – we must adapt to the situation around us or continue to be blindsided by dangerous developments in the future.
ErasaVir is redefining what hygiene means in a post pandemic world. Developed by US based Palani LLC, their first pair of products (a mouth and nasal spray respectively) aim to protect us from harmful pathogens after they enter our bodies. This internal hygiene complements our other daily hygiene activities like using masks, soap and sanitizers using toothpaste and probiotics externally. ErasaVir mouth and nasal sprays are the only available internal hygiene products of their kind – that can be safely used daily and on a life-long basis. All the ingredients in ErasaVir have been proven to be safe and categorised as GRAS (Generally Recognized as Safe) by the US FDA. In India, these products are approved under the department of AYUSH, owing to the plant origins of their active ingredients. They represent a new paradigm in hygiene, acting as daily companions which protect and reassure us as we navigate life, uninterrupted.
The ErasaVir platform inactivates (kills) various enveloped viruses (including SARS-CoV-2 and the Flu) and some other pathogens like harmful bacteria on contact, providing complete upper respiratory tract protection. The platform leverages lipid-dissolution technology in order to physically destabilise and inactivate these pathogens. This mechanism allows ErasaVir to function irrespective of variants and mutations within the viruses and bacteria, which is a massive advantage. There are many such microorganisms present in our environment, which can cause illnesses and inconveniences. By protecting us from a wide range of these pathogens, ErasaVir gives us the opportunity to breathe easier and not be anxious about falling sick all the time.
ErasaVir has a single goal – to redefine hygiene as we know it today. Such a product was relevant even before the pandemic started – anything that helps us avoid sickness is always welcome. But now, post-pandemic, the glaring need for such solutions has been made clearer than ever before. Our daily preventive measures to defend against pathogens that cause diseases are based on basic procedures that have seen little evolution over the years. ErasaVir seeks to push this segment further than it has ever been before – with a simple solution that is easy to understand and adopt, but scientific at its core. ErasaVir is safe, portable, suited for all age groups and easy to use at home, work, or play.
By providing people with a new set of tools that can protect them from hazardous pathogens on a daily basis, ErasaVir will improve the quality of life of users, leaving them better equipped to navigate a world in which falling prey to pathogens is becoming more common than ever. ErasaVir’s formulations are based on four decades of scientific literature, and have been tested thoroughly at an UN-affiliated BSL-3 lab facility, showing 100%efficacy. Further, the active ingredients and formulation itself, along with its methods of preparation, leverage proprietary technology fine-tuned by a team of veteran scientists. To top it off, the team is fortunate to be supported by business leaders in India and abroad. Some of these scientists and advisors are:
- Dr. Dino Rotondo – Senior Lecturer in Immunology, Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow UK.
- Dr. RBN Prasad – Former Chief Scientist and Head of the Centre for Lipid Research at CSIR-Indian Institute of Chemical Technology, Hyderabad.
- Dr. Suman Kapur – Senior Professor, Department of Biological Sciences at the Birla Institute of Technology & Science, Pilani (Hyderabad Campus).
- Dr. Kumaril Bhargava – CEO at Serentrix Therapeutics, USA. Previously at Pfizer, Abbott Labs, American Pharmaceutical Partners, Procter & Gamble and Johnson and Johnson.
- Dr. CB Bhattacharya – H.J. Zoffer Chair in Sustainability and Ethics at the Katz Graduate School of Business, University of Pittsburgh.
- Hari Menon – Founder and CEO of Bigbasket.com, India’s largest groceries delivery platform.
- Deepnath Roy Chowdhury – Founder and MD, Strassenburg Pharmaceuticals, and past president of the Indian Drug Manufacturers Association.
To bring these products to India, Palani LLC has collaborated with Strassenburg Pharmaceuticals – a respected ethical manufacturer and marketer of allopathic medicines with over 35 years of experience in the country. Over the past couple of months, Strassenburg has been collecting feedback and validation for ErasaVir from doctors around the country. After a very encouraging response and being medically validated, the team now sees the urgent need to reach consumers directly as well. The objective is to directly communicate and educate potential users about these products and establish ErasaVir as a long-term health partner to as many people as possible. The sprays are available for purchase on www.erasavir.com directly, in addition to Amazon, 1mg, Pharmeasy, SastaSundar, Frank Ross (more platforms and physical stores will be added as well as other distribution partners), and chemist stores across India. In addition to educating consumers, the ErasaVir team is also actively seeking to work with NGOs and government bodies to spread awareness around hygiene in India and around the world.
Anupam Dokeniya, Co-Founder of Palani LLC shared his views on their mission: ‘Palani LLC was founded in early 2020, as part of an attempt to provide people with solutions that would alleviate some of the daily issues faced by them during the pandemic. Owing to fifteen years of experience working with fatty acids in oncology, I was convinced that these molecules could be modified to also be efficacious against enveloped pathogens like SARS-CoV-2 (the virus responsible for the then global pandemic). This was scientifically validated and given shape with a well thought-out and researched scientific rationale by Dr. Dino Rotondo, an immunologist and pharmacologist, who has worked on fatty acids for several decades and produced pioneering work. As we move forward serving as many people as possible to ward off pathogens, Palani will also serve the larger need for consumer health’
Darpan Roy Chowdhury, Co-Founder of Palani LLC says: ‘In healthcare, like all other fields, tail-end events with high costs to society act as triggers for innovation. While the possibility of a pandemic had been discussed in smaller scientific circles, nobody was prepared for this level of loss and chaos. Intranasal products have traditionally dealt with issues like congestion and some brain conditions which respond better to intranasal drug delivery. The outbreak of a respiratory virus which spreads almost entirely through the upper respiratory tract is an ideal candidate for making innovators sit up and develop solutions which target this area. We think that developments in this delivery segment will continue to reach people as we rethink hygiene and the maintenance of suitable conditions in the upper respiratory tract. We are proud to be at the forefront of this segment and hope to provide multiple solutions to users around the world.’
Facebook Comments